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The non-medical use of prescription opioids has become the fastest growing drug prob-
lem in the United States. The economics literature offers little evidence about the
causal relationship between extending insurance coverage, which increases access to
opioids, and the prevalence of the epidemic. I leverage a non-linear difference-in-
differences design to examine the impact of the dependent coverage provision of the
Affordable Care Act (ACA) on the prevalence of prescription opioid misuse and abuse.
Consequently, I study some of the mechanisms driving my results. I draw on a sample
of responses of non-institutionalized individuals using data from the National Survey
of Drug Use and Health (NSDUH) from 2008 to 2014. I find that the expansion is
associated with an 11.2% decline in prescription opioid misuse and a 25% decrease in
opioid abuse among young adults. In addition, I find evidence of a possible substitution
effect in the setting in which young adults receive treatment for their drug disorders.
Results show that young adults are 18.6% more likely to receive outpatient treatment
as a consequence of gaining private coverage from the provision.
1
Acknowledgements
I would like to thank Dr. Partha Deb for his constant help and guidance throughout
the completion of this study. I would also like to express my gratitude to the faculty
of the Hunter College Department of Economics for providing me mentorship during
these two years in the graduate program.
2
Contents
1 Introduction and Motivation 4
2 Background 7
2.1 The Opioid Epidemic . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.2 The Affordable Care Act’s Dependent Coverage Provision . . . . . . . . 9
3 Review of the Literature 10
3.1 Medicaid Expansion, Full Implementation of the ACA and Medicare
Part-D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
3.2 The Affordable Care Act’s Dependent Coverage Provision . . . . . . . . 11
3.3 State Laws and Other Regulations Designed to Restrict Access to Opioid
Pain Relievers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
4 Methods 14
4.1 Non-linear Difference-in-Differences . . . . . . . . . . . . . . . . . . . . 14
5 Data 15
5.1 Outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
5.2 Summary Statistics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
6 Results 20
6.1 Health Insurance Status . . . . . . . . . . . . . . . . . . . . . . . . . . 20
6.2 Opioid Use Disorders Outcomes . . . . . . . . . . . . . . . . . . . . . . 21







1 Introduction and Motivation
The current opioid epidemic is the fastest growing drug problem in the United States.
Since its beginning in 1999, more than 400,000 people have died from a drug overdose
involving opioids (CDC, 2018)1. Deaths from prescription pain relievers have been
the dominant driver of the epidemic (Powell, Pacula & Taylor, 2015). In 2016, about
19,354 people died from overdoses involving prescription opioids (National Institute on
Drug Abuse, 2018).2 Due to the magnitude of the problem, in 2014 the Center for
Disease Control and Prevention added preventing opioid abuse to its list of top five
public health challenges (Kolodny et al., 2015).
Overdose deaths are, however, extreme cases of the problem. The epidemic is
much more severe when other factors are considered such as morbidity related to the
prevalence of opioid misuse. The share of individuals using opioid pain relievers non-
medically has been growing steadily in the past decade, and to an extent that it is now
being considered a public health crisis. (Kolodny et al., 2015)
Young adults are particularly at higher risk of having opioid pain reliever disorders.
(Alpert, Pacula & Taylor, 2015; Grecu, Dave & Saffer, 2017). In 2016, 3.3 million
people in the United States reported having misused opioid pain relievers, with young
adults accounting for the largest percentage. About 7.1% of individuals aged 18-25
report having misused pain relievers in the past year (SAMHSA, 2017). 3 .
An early provision of the Affordable Care Act might have contributed to the prob-
lem. In 2010, the Obama administration passed a mandate that allowed individuals
to remain under their parents’ private health insurance coverage until they turn 26
years of age. The young adult provision expanded coverage to more than two million
individuals (Antwi, Moriya & Simon, 2015). Spillovers from this coverage extension
may be reflected in the rate of opioid misuse.




2016.htmopioid. Accessed on 2018-12-22
4
In this study, I examine the impact of the young adult provision on the prevalence
of opioid pain reliever misuse and abuse. I draw on a sample of responses of non-
institutionalized individuals using data from the National Survey of Drug Use and
Health (NSDUH). Following the literature that has examined the dependent coverage
provision and the opioid epidemic, I apply a non-linear difference-in-difference model.
I classify individuals aged 22-25 in the treatment group and compare them to a control
group of older of individuals aged 26-29 that were not affected by the provision. I
consider three sets of outcomes: health insurance status, opioid use disorders measured
by opioid misuse and abuse, and the settings in which treatment for substance use
disorders is received.
The underlying hypothesis of this study is that access to the healthcare system,
through the obtainment of private insurance coverage, can impact opioid pain reliever
misuse and abuse in opposite directions through different mechanisms. First, gaining
private coverage increases the demand for medical care, which can also increase access
to prescriptions for pain relievers from physicians. This may provide incentives for
misusers to get involved in unscrupulous schemes to obtain pain relievers. For example,
misusers might seek prescriptions from multiple doctors, a practice is known as ”doctor
shopping”. If this is the case, one can expect the prevalence of pain reliever misuse to
rise due to the negative externality produced by the expansion to opioid access.
Alternatively, acquiring private health insurance coverage improves access to sub-
stance abuse treatment. The gain of private coverage provides a new source of pay-
ment for substance use disorder treatment, reducing the out-of-pocket costs for newly
insured individuals (Saloner et al., 2018). If individuals decide to take advantage of
these benefits and seek rehabilitation and detoxification therapies, one can expect the
prevalence of opioid misuse to fall. This effect would be greater in magnitude, partic-
ularly among of young adults with substance use disorders given their historically low
rates of insurance.
The ACA’s dependent coverage provision could also change the settings and types
of care received by individuals needing treatment, especially among the previously
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uninsured. Young adults with opioid use disorders may replace daily visits to pub-
lic sector, safety net providers, that accept uninsured patients for medication-assisted
treatment (MAT) provided at a private physicians office (Saloner et al., 2018; Mein-
hoffer and Witman, 2018). Saloner et al. (2018) find that admissions of young adults
to specialty inpatient treatment facilities declined by 11% after the ACA’s dependent
coverage mandate went into effect. Similarly, Meinhoffer and Witman (2018) find that
the 2014 Medicaid expansion resulted in increased admissions to treatment in out-
patient settings for rehabilitation involving MAT. Meanwhile, inpatient treatment for
rehabilitation remained unchanged. In addition, entry into coordinated care can signif-
icantly improve individuals’ overall health. Access to suitable care and improvements
in young adults’ health may lead to a decline in the prevalence of opioid misuse among
this group.
Newly insured individuals will be subject to prescription laws and regulations once
they formally enter the health care system. This can potentially increase the difficulty
for misusers to obtain opioids regardless of the recently gained access to prescriptions.
Evidence on the effect of these programs, such as Prescription Monitoring Programs
(PDMPs), on opioid-related outcomes is mixed. Early studies find no significant im-
pact of these programs on reducing the prevalence of opioid misuse. However, recent
work on this topic documents that ”mandatory-access” provisions have significantly
reduced measures of opioid misuse as well as overlapping prescribing and doctor shop-
ping behavior (Jena et al., 2014; Buchmuller & Carey, 2010; Grecu et al., 2017; Bao et
al., 2016; Ali et al., 2017).
The impact of the ACA’s private coverage expansion on opioid misuse is ambiguous
and therefore subject to an empirical study. The economics literature, thus far, has
offered little evidence on the externalities associated with extending medical access
to populations with disproportionately low rates of insurance such as young adults
with possible drug disorders. The ACA’s young adult provision provides a unique
opportunity to study the causal implications and mechanisms underlying the opioid
epidemic. My analysis exploits the exogenous expansion in health insurance coverage
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among a segment of young adults to explore the effects of the mandate on the prevalence
of opioid misuse and abuse.
This paper makes three important contributions to the growing literature on the
opioid crisis. First, to the best of my knowledge, this is the first study that uses the
ACA’s dependent coverage provision, as a natural experiment, to look at the exter-
nalities resulting from extending private coverage to young adults on the prevalence
of opioid misuse and abuse. Second, it extends prior studies to test the impact of the
expansion on treatment for substance use disorders using four years of post-enactment
data. Third, I implement a non-linear difference-in-differences design to obtain esti-
mates on the marginal effects of the young adult provision.
The rest of the paper is organized as follows. In section 2, I provide a background on
the opioid epidemic and the ACA’s dependent coverage provision. Section 3 presents
a review of results from the recent literature. Section 4 describes the data used and
provides summary statistics. Section 5 describes my empirical approach. In section
6, I present results for the marginal effects of the young adult provision. Section 7
explains the limitation of the study. Section 8 presents a thorough discussion of the
results obtained from the non-linear difference-in-differences design. Section 9 contains
the conclusion.
2 Background
2.1 The Opioid Epidemic
It is believed that the current opioid epidemic began in the late 1990s. Today, it has
become the largest and fastest growing drug problem in the United States (Meinhofer
and Witman, 2018). From 1999 to 2017, more than 400,000 people have died from an
overdose involving some type of opioid (prescription and illicit opioids). In 2017 alone,
approximately 70,200 people died from an opioid overdose (CDC, 2018). The figure
from 2017 is six times larger in comparison to 1999. The unprecedented increase in
opioid abuse, has led the Center for Disease Control and Prevention to call this the
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worst drug epidemic in U.S. history (Kolodny et al., 2015).
Unlike other illegal drugs, opioid pain relievers, which historically have been the
main driver of the epidemic, have legitimate medical functions (Powell, Pacula &Tay-
lor, 2018). Several organizations including the American Pain Society, the American
Academy of Pain and Medicine, and other pain patient groups advocated for a cam-
paign which encouraged health care professionals to assess pain as the fifth vital sign
and urged a more aggressive use of opioids to treat chronic non-cancer pain (Kolodny
et al., 2015). Shortly after, as a consequence of the campaign, physicians started using
opioid pain relievers as first-line therapy for treating chronic pain. However, they often
neglected the high risks for addiction associated with pain relievers.
Over the years, physicians developed over-prescribing behaviors, especially those
with limited training in pain management such as primary care doctors. As a result,
the total number of prescriptions filled for opioid pain relievers more than doubled to
274 million in just one decade (Dave, Deza and Horn, 2018). For example, the number
of Oxycontin prescriptions for non-cancer pain increased nearly tenfold from 1999 to
2002 (Alpert et al., 2018). The increased supply of opioid pain relievers led to high
levels of diversion to non-medical use fueling the epidemic.
Legitimate prescriptions filled by physicians remain as an important source of
supply of opioids for misusers. In 2016, about 4.3 million people indicated that
they obtained pain relievers through prescriptions either from one or multiple doc-
tors (SAMHSA, 2017). This statistic could be even greater if we consider the fact that
prescription for pain relievers are also a significant supply source to tertiary channels
such as street dealing and misusers’ friends and relatives (Simeone, 2017). Alpert et al.
(2016) find evidence of plausible spillovers from the increased access to opioids given
by the implementation of Medicare Part D. This relative expansion in opioid supply
resulted in the escalation of admissions for opioid abuse treatment and opioid related
mortality among younger individuals who were not eligible for the program’s benefits
(Alpert et al., 2016). These effects were, not surprisingly, higher among young adults.
The economic burden of the current opioid epidemic including health care, criminal
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justice costs, and costs due to the loss in productivity was estimated to be around $78
million in 2013 (Florence et al.,2016).
2.2 The Affordable Care Act’s Dependent Coverage Provision
The main objective of the Patient Protection and Affordable Care Act (ACA) has been
to ”expand health insurance coverage to populations with historically limited access to
healthcare services” (Saloner, Antwi, Maclean & Cook, 2018). The dependent coverage
mandate is an early provision that allowed young individuals to remain as dependents
under their parents’ private health insurance plans until they turn 26 years of age.
The provision was implemented in September 2010 with the intention of addressing
the issue of the historically high rates of uninsured young adults relative to other
age groups. Prior to the ACA, the loss of insurance coverage among the non-elderly
peaked at ages 21 to 23 and close to 40% (Antwi, Moriya & Simon, 2013). The main
reason for young adults’ lack of coverage was because they aged out of their parents’
private plans. Insurers would normally drop non-student dependents at age 19 and
student dependents at age 23 (Deb & Norton, 2018). Empirical evidence shows that
the expansion achieved its desired goal by increasing the number of insured young
adults by over two million individuals (Antwi, Moriya and Simon, 2012; Sommers,
Buchmuller, Carey & Kronick, 2012). In addition, Sommers et al. (2013) find a 5.1
percentage point increase in private insurance coverage among individuals aged 19-25
using data from the 2005-2011 National Health Interview Survey (NHIS).
The prevalence of mental health and substance use disorders peak at young adult-
hood (SAMHSA, 2017), and insurance coverage has been historically low among the
overall population with behavioral problems. Because of these reasons, the dependent
coverage provision has the potential of being substantially important for young adults
with such disorders by providing them with coverage for treatment. In the past, addic-
tion services were provided in separate specialty care addiction treatment programs.
Financing for such services was provided by the government and other public sources
separately from healthcare coverage. (McLellan & Woodworth, 2014). To address this
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issue, the ACA requires health insurance plans to offer coverage for substance use dis-
orders as one of the ten essential health benefits (McLellan & Woodworth, 2014). This
means that the provision has the potential to curb the opioid epidemic by extending the
availability of coverage to previously uninsured young adults. A priori, it is uncertain
whether the newly insured will take advantage of this benefits.
3 Review of the Literature
3.1 Medicaid Expansion, Full Implementation of the ACA
and Medicare Part-D
A substantial portion of the literature has looked at the effect of other provisions of the
ACA on substance and opioid use disorders. The literature agrees that expansions of
insurance coverage have increased utilization for substance and opioid use treatment.
There is also evidence that insurance coverage has decreased the financial barriers to
treatment, as well as the share of uninsured individuals.
Meinhoffer & Witman (2018) look at the impact of the 2014 ACAs Medicaid ex-
pansion on treatment utilization for opioid use disorders using data from 2008-2016
TEDs. They find that treatment admissions increased by 5.4 percentage points (18%)
in expansion states. This overall increase in treatment utilization was driven by a
substantial increase in Medicaid coverage (113%). Their results show evidence of a
dynamic substitution towards outpatient treatment for opioid addiction in expansion
states. They find that outpatient treatment involving MAT increased by 5.3 percentage
points. Meanwhile, inpatient treatment for opioids remained unaffected.
Ali et al., (2015) and McKenna (2017) analyze the impact of the national imple-
mentation of the ACA. They find that the full expansion of health insurance coverage
increased treatment utilization for substance and opioid use disorders among adults.
Although, this effect is conditional on perceiving a need for treatment (Ali et al., 2015).
The share of the uninsured declined as a result of the ACA implementation. McKenna
(2017) finds that after the coverage expansion, adults with opioid use disorders were
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more likely to report that insurance paid for their treatment.
Powell et al. (2015), use the introduction of the Medicare Prescription Drug Benefit
Program (Medicare Part-D) to estimate the effects of the differential increased supply
of opioid pain relievers in states with larger portions of elderly individuals on abuse and
overdose deaths among populations that are not eligible for Part-D. They show that
the increased supply of opioids resulting from the implementation of Part-D caused
economically important levels of diversion for non-medical purposes. They find that a
10% increase in opioid medical distribution leads to a 7.4% increase in opioid related
deaths and a 14.1% increase in substance abuse treatment admissions. Effects were
larger among young adults.
3.2 The Affordable Care Act’s Dependent Coverage Provision
The literature on the dependent coverage provision coincides that the expansion of pri-
vate coverage reduced the share of uninsured young adults. Furthermore, the provision
decreased out-of-pocket spending, which increased the demand for medical services.
The literature on behavioral health gives mixed results. On one hand, the provision
has increased treatment utilization for mental health services, but on the other hand,
there exists limited evidence of the expansions' effect on treatment for substance use
disorders.
Antwi, Moriya & Simon (2015) use data from the Nationwide Inpatient Sample
(NIS) from 2007 to 2011 and show that the prevalence of uninsured young adults
hospitalized declined by 10.8% as a result of the expansion. Inpatient hospital visits
increased by 3.5% among individuals 23-25 years of age, while, mental health visits
also increased by 5.5%.
Ali et al. (2016) and Deb & Norton (2018) show evidence of a decline in healthcare
spending caused by the provision's implementation. This could have led to changes
in location settings where young adults seek attention. For example, Deb & Norton
(2018) find that the number of office-based visits increased by 42.7 percentage points,
while there was a small reduction of 4.3 percentage points in emergency room visits.
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These results were robust across several types of non-linear specifications.
At least two studies have examined the impact of the dependent coverage provision
on treatment for mental and substance use disorders. Saloner et al. (2014), using
data from the 2008-2012 NSDUH find that mental health treatment increased by 5.3
percentage points for a subset sample of individuals aged 18-25 with possible mental
disorders. For people using mental health treatment, uninsured visits declined by 12.4
percentage points. Whereas, the share of young adults with private insurance increased
by 12.9 percentage points. The authors were unable to find any effect of the provision on
treatment utilization for substance use disorders. In a different study, however, Saloner,
Antwi, Maclean and Cook (2018) use admissions data from the Treatment Episode
Data Set (TEDS) and find that admissions to treatment for substance use disorders
declined by 85.6 percentage points (11%) after the expansion for individuals ages 21-
24. In addition, the share of young adults covered by private insurance increased by
5.4 percentage points and the share with private payments increased by 3.7 percentage
points.
The existent literature has studied the effects of extending health insurance coverage
on treatment utilization among young adults with substance use disorders. However,
no study has focused on the unintended effects that the dependent coverage provision
has had on the prevalence of non-medical use of opioid pain relievers among young
adults.
3.3 State Laws and Other Regulations Designed to Restrict
Access to Opioid Pain Relievers
State level Prescription Dug Monitoring Programs (PDMPs) are among the most stud-
ied policies designed to combat the current prescription opioid crisis.
PDMPs are statewide databases designed to curtail access to prescription opioids by
tracking the prescribing and dispensing of controlled substances (Dave, Deza & Horn,
2018). The literature provides limited evidence on the efficacy of these programs.
Early studies find no effects of PDMPs on opioid related outcomes. However, recent
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studies have identified that PDMPs with mandatory provisions implemented in some
states have reduced the number of opioid related admissions to treatment and doctor
shopping behavior.
Jena et al. (2014) use data from a national sample of U.S. Medicare beneficiaries
in 2010 and find that PDMPs have no impact in the number of prescriptions filled
by multiple providers. Ali, Classen, Mutter and Novak (2017) use 2004-2014 NSDUH
data to examine the impact of PDMPs on individual level opioid related outcomes
among adults. They find no significant impact of a PDMP implementation on the
non-medical use, abuse and initiation of opioid pain relievers. In addition, they do not
find a significant effect on initiation and use of heroin. However, they show evidence
of a reduction in doctor shopping behavior caused by the implementation of PDMPs.
Furthermore, Bao et al. (2016) assess the effects of PDMP implementations on the
prescribing of opioids with the purpose of managing pain in the ambulatory care sector.
Results from their analysis indicate that the implementation of PDMPs are associated
with a 30% reduction of prescriptions for schedule II opioids, relative to the rate of
prescribing prior implementation.
Grecu, Dave and Saffer (2017) use data from the Treatment Episodes Data Set
from 2002 to 2016 to determine the differential effects of mandatory access provisions
for PDMP utilization. Using a difference-in-difference model, the authors find that the
adoption of a mandatory access provision reduced opioid related treatment admissions
by 20 to 26%, relative to the sample mean for adopting states in the year prior im-
plementation. The authors'results suggest that there are some heterogeneous effects
among age groups. Their estimates indicate that the impact is larger for young adults.
Mandatory access PDMPs reduced opioid related admissions by 5.8 fewer admissions
per 10,000 individuals ages 18 to 24. Buchmuller and Carey (2018) apply difference-
indifference models to aggregated claims data from the Medicares prescription Drug
Program (Medicare Part-D) to evaluate the effect of PDMPs on prescription drug
utilization among Medicare Beneficiaries. The authors' results show that mandatory
access programs decreased the share of Part-D beneficiaries taking opioids by 2.4%.
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They also find evidence of a 6% decline in the share of opioid takers with overlapping
claims and a 5% decline in the share of takers with more than seven-months supply.
However, their results do not find a significant effect on opioid poisoning incidents. In
addition, the previous studies show that those PDMPs that do not require providers'
participation are not effective in reducing non-medical use of prescription opioids.
In another largely recognized study, Alpert, Powell and Pacula (2018) use the intro-
duction of an abuse deterrent version of Oxycontin as a natural experiment to examine
the implications of a supply side disruption of a highly abusable opioid. The au-
thors leverage data from multiple sources including the National Survey on Drug Use
and Health (NSDUH), administrative data from the Drug Enforcement Administration
(DEA) as well as data from the National Vital Statistics System (NVSS). Exploring
cross state variation in Oxycontin exposure, they find that states with higher rates of
Oxycontin misuse experienced disproportionate increases in heroin deaths. Specifically,
a 1 percentage point increase in initial Oxycontin exposure led to an increase of 2.2
heroin overdose deaths per 100,000 people in 2013. Their findings suggest a substitu-
tion effect towards illegal opioids produced by the supply disruption of Oxycontin.
4 Methods
4.1 Non-linear Difference-in-Differences
Following the literature on the dependent coverage provision, I use a non-linear difference-
indifference to derive the incremental effects of the policy. In non-linear DD models,
the identification of the sign and magnitude of the treatment effect is not as easily
derived as in linear DD models. Puhani (2012) explains that for non-linear models, the
treatment effect is not a simple cross difference, but a difference between cross differ-
ences. An easier way to motivate the treatment effect in a non-linear DD model is to
view the model in a potential outcomes framework. In this framework, the potential
outcome corresponding to treatment in the treated group is observed. The potential
outcome corresponding to the treated group in the treated period not receiving treat-
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ment is not observed, but is estimated in the regression model. The treatment effect
is an estimate of the difference between these two potential outcomes.
For simplicity, consider a binary indicator for the group of individuals of ages 22-25
(Treat =1) denoting the treatment group, a binary time indicator (Post =1) denoting
the years after the implementation of the young adult provision, and a vector X de-
noting a set of covariates that control for demographic characteristics. Then, consider
a logit regression specification in a DD design for binary outcomes such as insurance
status, opioid misuse and abuse, and treatment settings for substance use disorders:
E[Y ] = Λ(β0 + β1Treat+ β2Post+ β3(Treat ∗ Post) +XΘ) (1)
Then Puhani (2012) shows that the treatment effect is given by
τ = E[Y 1|Treat = 1, Post = 1, X]− E[Y 0|Treat = 1, Post = 1, X] (2)
Where Y 1 and Y 0 denote potential outcomes with and without the treatment policy
respectively. In the regression specification,
τ = Λ(β0 + β1 + β2 + β3 +XΘ)− Λ(β0 + β1 + β2 +XΘ) (3)
In addition my models include age and year fixed effects that control for time invariant
determinants of Y. Standard errors are clustered by age and year. All models include
indicators for age group and for the time period when the individual is observed. In
addition, the preferred specification includes covariates that control for gender, race or
ethnicity and for residence in a metropolitan area. Controls for education and income
levels were not included in the preferred specification due to a concern for potential
endogeneity which could bias my estimates.
5 Data
This study utilizes pooled data from the 2008-2014 National Survey of Drug Use and
Health (NSDUH).4 The NSDUH is an annual cross-sectional, nationally representative
4Data was obtained from https://www.datafiles.samhsa.gov/study-series/national-survey-drug-
use-and-health-nsduh-nid13517
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survey of non-institutionalized individuals in the United States. It is conducted by the
Substance Abuse and Mental Health Services Administration (SAMHSA). The NSDUH
collects detailed information on the use and abuse of drugs and alcohol, mental health
problems and behavioral health treatment utilization. The survey provides informa-
tion on self-reported insurance status as well as non-medical opioid pain reliever misuse
within the past year. It also asks respondents questions to assess symptoms of opioid
use disorders (dependence and abuse) using screening criteria from the Diagnostic and
Statistical Manual of Mental Disorders (DMS-IV) (Ali et al., 2015). These measures
capture personal, legal and school or employment problems related to the non-medical
use of opioid pain relievers as well as problems in reducing their non-medical consump-
tion (Saloner & Cook, 2014). For example, if respondents report having misused opioid
pain relievers, they would be asked questions about dependence such as whether they
experienced withdrawal symptoms after cutting back on the substance. Respondents
are also asked questions regarding abuse symptoms. For example, whether they have
had any problems with family, friend or with the law, related to their misuse of opioids
during the past year.Also, whether they have continued misusing opioids despite the
occurrence of these problems.
The NSDUH is a convenient source of data for the study of the opioid epidemic for
two reasons. First, questions regarding opioid pain reliever misuse direct respondents
to provide information about prescription pain relievers specifically, and not over-the-
counter painkillers such as Aspirin. Second, respondents are told to report on their
non-medical use of opioid pain relievers only. The NSDUH defines misuse as either: a)
using pain relievers not prescribed to the respondent; or b) the respondent took the
drug only for the experience or feeling caused as a result of taking the drug.
5.1 Outcomes
This paper examines several sets of outcomes which include health insurance status,
opioid use disorders, and the setting in which treatment for substance use disorders
was received.
16
Health insurance status is measured by the type of insurance coverage reported
by respondents (e.g. uninsured, covered by private health insurance, and any type of
health insurance coverage. These three variables are binary and obtain the value of
one if the observation reports having any type of insurance coverage, being covered by
a private plan, and being uninsured, and zero otherwise.
The set of opioid use disorders outcomes are measured by several dependent vari-
ables. First, I look at self-reported non-medical use of opioid pain relievers in the past
month and year. Misuse of opioid pain relievers are binary variables that obtain the
value of one if the individual reports having misused opioids in the past month and
year, and zero otherwise. In order to mitigate recall bias and for consistency with other
variables, misuse in the past year is the preferred outcome.
In addition, two outcomes measuring the respondents abuse and dependence of
pain relievers are considered. The first outcome includes both categories: abusers and
dependents. The second outcome excludes dependents in order to estimate the impact
of gaining coverage on opioid abuse.
As mentioned above, the NSDUH determines whether individuals had problems
concerning opioid abuse and dependence based on criteria from the Diagnostic and
Statistical Manual of Mental disorders, Fourth edition (DSM-IV). Dependence and
Abuse of pain relievers are two mutually exclusive categories with dependence taking
precedence. Respondents are categorized as having pain reliever dependence if they
report a positive response to three or more of the six questions regarding substance
dependence plus a seventh question regarding withdrawal symptoms. Likewise, respon-
dents are categorized as having abused pain relievers if they report a positive response
to one or more of the four questions regarding social problems related to opioids and
were determined not to be dependent upon pain relievers.
Outcomes for substance use treatment settings are measured by the type of location
where respondents received current or past year treatment for their drug disorders.
Following Ali et al. (2015) I have aggregated treatment locations into inpatient setting
and outpatient setting. Inpatient setting is a binary variable that takes the value of
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one if individuals have received treatment overnight at a hospital or if individuals have
received treatment in a residential rehabilitation facility and zero otherwise.
In a similar manner, the variable for outpatient treatment takes the value of one if
individuals have received treatment for their drug disorders at a rehabilitation facility
(not overnight), mental health care center or a private doctor's office in the past year
and zero otherwise. Also, a variable for treatment received at the emergency room is
included as an outcome.
This study does not include those who received treatment through self-help groups.
This is because these types of treatments are usually not covered by health insurance
and therefore, do not relate to the insurance coverage expansion (Ali et al., 2015). One
limitation of the NSDUH is that treatment for opioid use is not reported by location.
Instead, the outcomes aggregated by treatment setting include other drugs such as
cocaine, heroin, tranquilizers and stimulants in addition to pain relievers. However,
the survey reports opioid treatment received at any location. I consider this variable
to estimate the overall impact of gaining insurance coverage on utilization for opioid
treatment.
5.2 Summary Statistics
The data restricted to 22-29-year-old individuals has 18,849 observations. Table 1
reports summary statistics for treatment and control groups in the pre-expansion period
(2008, 2009, 2010) and in the full study period. As expected, demographic means are
similar among the treated and control groups with the exemption of their marital
status, education and income levels. Among the 22-25 year-olds in the treated group,
53.3% are females, 12.7% are black, 17.7% are Hispanic, 9.4% are from another race,
and 21.7% are married in the pre-mandate period. Among the 26-29-year-old control
group 53.6% of individuals are females, 11.9% are black, 19.8% are Hispanic, 9.9% are
from another race and 40.6% are married in the pre-expansion period.
The younger treated group is, on average, more educated than the older compari-
son group at the high school and some college level with 29.2% and 30.6% respectively.
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Whereas, these rates for the older group are 27.9% and 26.4% respectively. How-
ever, young adults are less educated at the college or higher education level (25.7%).
Whereas, 30.3% of older individuals have graduated college.
Young adults are relatively poorer than their counterparts as 29.7% of individuals
in this group have a total family income of less than $19,000 per year, 39.5% have a
total family income between $20,000 and $49,000 per year, 14.8% have an annual family
income between $50,000 and $74,000 , and only 16% earn $75,000 or more annually
in the pre-expansion period. Whereas, 21.2% of older individuals have a total family
income of less than $19,000 per year, 40.87% have a total family income between
$20,000 and $49,000 per year, 19.2% have an annual total family income between
$50,000 and $74,000 and 18.78% earn $75,000 or more annually in the pre-expansion
period.
As shown in Table 2, Insurance status differs substantially among treated and
control groups in the pre-expansion period. Only Medicaid coverage rates are similar for
both groups with 13.9% of 22-25 year-olds and 13.5% of 26-29 year-olds being covered
through Medicaid. Among Young adults, 69.7% have any type of health insurance
coverage, 51.4% report having private insurance coverage, and 30.3% are uninsured.
Whereas, 73% of older adults have any type of health insurance coverage, 56.1% report
having private insurance coverage, and only 27% are uninsured.
Table 3 presents descriptive statistics for opioid use disorders. In the pre-expansion
period, opioid use disorders are more prevalent on young adults. Among the treated
group, 10.7% and 4.5% of individuals report having misused opioid pain relievers in
the past year and past month respectively. About 1.76% of young adults are opioid
pain reliever dependents or abusers. Among the older comparison group, 8.3% and
3.2% of individuals report misusing opioid pain relievers in the past year and month
respectively. Moreover, about 1.2% meet the criteria for opioid pain reliever dependence
or abuse.
Table 4 shows that treatment rates for drug disorders are higher for young adults in
the pre-expansion period. About 5.8% of individuals report having received treatment
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in an emergency room, 19.9% report having received treatment in an inpatient setting
and 39.9% received outpatient treatment in the past year. Among the control group,
4.9% of older individuals report having received treatment at the emergency room,
18.1% received inpatient treatment and 49% received treatment in an outpatient setting
during the past year. Individuals aged 22-25 received lower rates of treatment for
opioid use disorders than 26-29-year-olds. About 24.8% of young adults report having
received treatment for their opioid use disorder in the past year. Whereas, 25.49% of
older adults received treatment for this condition.
6 Results
6.1 Health Insurance Status
Table 6 contains marginal effect estimates of the difference-in-difference model for the
causal impact of the young adult provision on health insurance status using logit re-
gressions along with controls, and age and year fixed effects. After the implementation
of the mandate, the likelihood of young adults having any type of health insurance cov-
erage increased by 6.4 percentage points relative to older adults. This is a statistically
significant increase of 9.18% from the pre-expansion baseline mean.
The increase in insurance coverage is largely driven by the increased share of pri-
vately insured young adults. Private health insurance coverage for young adults in-
creased by 6.7 percentage points, which represents a 13.05% increase from the baseline
mean relative to adults aged 26-29. The increase in private insurance coverage was
substantially offset by a 6.4 percentage point decrease in uninsured young adults rela-
tive to the comparison group. This represents a 21.1% decline from the baseline mean.
These results are consistent in direction and significance with other studies. (Antwi et
al., 2013; Saloner et al., 2018).
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6.2 Opioid Use Disorders Outcomes
Table 6 contains regression results for the impact of the young adult mandate on opioid
use disorder outcomes. Results indicate that the expansion had a statistically signifi-
cant impact in reducing reported non-medical use of opioid pain relievers in the past
month and year. Relative to adults aged 26-29, young adults' opioid pain reliever mis-
use in the past month and year declined by 1.1 and 1.2 percentage points, respectively.
This represents a 24.4% reduction in past month misuse and a 11.2% reduction in mis-
use of pain relievers in the past year. Also, results show suggestive evidence that the
insurance expansion is associated with declines in the rates of dependence and abuse
of opioid pain relievers.
As described above, the NSDUH categorizes individuals as pain relievers depen-
dents or abusers using the DSM-IV criteria. Column 3 shows results for the effect of
the expansion on opioid pain reliever dependence or abuse combined. The expansion
is associated with a 0.3 percentage point decrease in pain reliever abuse or dependence
in the past year among individuals aged 22-25. This represents a 16.6% reduction in
the share of young adults categorized with either condition in the past year. Excluding
opioid dependents, column 4 shows that after the expansion young adults are 0.1 per-
centage points less likely to abuse opioids relative to the control group. This represents
a 25% decline from the baseline mean. These effects are statistically significant at the
10% level.
One of the limitations of using the publicly available version of the NSDUH is that
it does not include state identifiers. Therefore, I am unable to control for state-level
laws such as prescription drug monitoring programs (PDMPs) that restrict access to
prescription pain relievers. Hence, there exists a concern for potential endogeneity
as these declines in opioid pain reliever measures may not be caused by increased
access to private insurance. However, Ali et al.n(2017) using the NSDUH, find no
statistically significant impact of two measures of PDMPs implementation on pain
reliever misuse, past-year dependence and abuse and initiation of non-medical use of
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painkillers. Similarly, other studies find no evidence of PDMPs being effective on
curbing the prescription opioid crisis, especially if providers are not required by law to
utilize these programs (Grecu et al., 2017; Buchmuller Carey, 2017; Dave et al., 2018;
Jena et al., 2014).
6.3 Treatment for Substance Use Disorders
A possible mechanism that can explain the decline in opioid misuse among young adults
is the increased access to drug treatment caused by the exogenous gain of private health
insurance. As described above, the sudden gain of health insurance may serve as an
incentive for individuals to increase their demand for drug treatment and other health
services. Most importantly, gaining private health insurance provides an incentive for
young adults with drug disorders to substitute expensive inpatient treatment at hos-
pitals and rehabilitation facilities for relatively less expensive treatment in outpatient
settings, such as medically assisted treatment (MAT) provided at a private doctor’s
office.
Table 7 contains regression results for the impact of the ACA provision on the
utilization of treatment for substance use disorders. Column 1 shows that the expansion
did not have any impact on treatment received at the emergency room as the coefficient
is not statistically significant. Column 2 suggests that after the expansion, individuals
aged 22-25 were 4.1 percentage points less likely to receive inpatient treatment relative
to the control group. This represent a 20% decline from the pre-expansion mean. The
coefficient, however, is not statistically significant at conventional levels.
Column 3 shows that there is a statistically significant increase in outpatient treat-
ment associated with gaining private health insurance. After the implementation of
the young adult provision, individuals in the treated group were 7.4 percentage points
more likely to receive treatment in outpatient settings. This marginal effect represents
an 18.6% increase from the pre-mandate baseline mean. Column 4 provides suggestive
evidence of an increase of 0.9 percentage points in treatment for opioid pain reliev-
ers. This represents a 3.63% increase from the baseline mean among young adults.
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However, this effect is not statistically different from zero.
Overall, these results suggest a potential substitution effect from young adults with
substance use disorders. Individuals in the treated group are more likely to seek outpa-
tient treatment as a result of obtaining private coverage. These results are consistent
with those previously found in the literature (Meinhoffer & Witman, 2014).
7 Limitations
There are some limitations in this study that should be considered. First, the Na-
tional Survey of Drug Use and Health data is a survey that measures stigmatized
conditions and behaviors. Therefore, there are some concerns about non-response and
social desirability bias. However, the surveyors mitigate these factors by using audio
computer-assisted self-interviewing and survey instruments designed to reduce such
biases (Saloner et al., 2014).
Second, since the NSDUH is a self-reporting survey, there exists a potential concern
for recall bias and measurement error. Individuals are directed to report their opioid
misuse in the past year and past month and treatment received in the past year. How-
ever, respondents might report answers outside of these time frames. Also, individuals
in 2011 might report opioid pain reliever misuse or treatment received in 2010 when
the expansion was not fully implemented. This would understate the impact of the
policy.
Third, for reasons of data confidentiality, the NSDUH does not report individuals’
age as a continuous variable. Therefore, I cannot exclude 26 year-olds from the analysis
as it is commonly practiced in the literature.
Fourth, the difference-in-differences design allows me to control for time-varying
factors that might be correlated with insurance coverage and opioid pain reliever mis-
use, as well as age and year fixed effects. However, given that the publicly available
data from the NSDUH does not report state identifiers, I cannot control for other
simultaneous state-level programs such as PDMPs that are designed to curve prescrip-
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tion for highly addictive drugs. Also, I cannot rule out the influence of other legislation
that occurred prior or during the study period such as the Mental Health Parity and
Addiction Equity Acts.
Fifth, I was not able to observe changes in dependent coverage versus changes in
other types of private coverage since the NSDUH does not specify if whether coverage
is provided directly to the individual or if the person is under someone else’s plan.
8 Discussion
A fully comprehensive analysis of a provision extending health insurance coverage to
a large underserved population must account for the possible externalities that the
mandate may produce such as opioid use and abuse. Substance use disorders, in
general, are important to examine because they have a high prevalence among young
individuals and insurance coverage has been historically restricted (Saloner et al., 2018).
Consequently, I examine changes in misuse and abuse of opioid pain relievers among
adults aged 22-25 before and after the implementation of the 2010 ACA provision that
allowed these individuals to remain under their parents' private plans.
Several important findings emerge from my analysis. This paper builds on the
growing literature that documents that the dependent coverage provision increased
health insurance coverage and demand for care. (Antwi et al., 2015; Saloner et al., 2014;
Ali et al., 2016; Saloner et al., 2018). I find that the provision achieved its intended
goal of increasing coverage among young adults. The share of privately insured 22-25-
year-olds increased by 13% as a result of the expansion relative to a comparable group
of individuals aged 26-29. This effect was offset by a 21.1% decline in uninsured young
adults.
In addition, I find evidence of a reduction in the prevalence of opioid pain reliever
misuse and abuse associated with the obtainment of private coverage from the ACA’s
provision. A priori, the effect of extending medical access to opioid prescriptions to
a population with higher risks of addiction is ambiguous. Often, increased access to
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opioid pain relievers results in diversion towards non-medical use. (Powell et al., 2015).
Counter to this hypothesis, results show that the expansion of private coverage caused a
decline of 11.2% on the prevalence of opioid non-medical use among young adults. More
importantly, after the implementation of the dependent coverage the share of young
adults with opioid use disorders (dependence or abuse) declined by 16.6%. Similarly,
after excluding individuals diagnosed with opioid dependence, I find that the share of
young adults abusing pain relievers declined by 25%.
A possible mechanism that can be driving the decline in the prevalence of opioid
abuse among young adults is the increased access to drug treatment caused by the
exogenous gain of private health insurance. In fact, I find that young adults are 18.6%
more likely to receive treatment for substance disorders in outpatient settings, which
includes mental health centers and private doctors’ offices. On the other hand, the
provision did not have any impact on treatment received as an inpatient. Nonetheless,
the sign of the estimate presents suggestive evidence that inpatient treatment declined
among young adults.
One can infer a substitution effect on treatment settings caused by the expansion.
Some young adults may have replaced specialty rehabilitation and detoxification treat-
ment in public settings for similar care in non-residential rehabilitation centers, mental
health centers, and private doctors’ offices. Substitution across settings could be ben-
eficial for young adults as it more appropriately places them in more suitable and
cost-effective care. (Saloner et al., 2018; Meinhoffer & Witman, 2018). Furthermore,
outpatient services deliver more personal and confidential care. This is important be-
cause the primary reason for patients not seeking treatment is not perceiving a need
for it (Ali et al., 2015).
Also, outpatient rehabilitation services are a more efficient way of curbing addiction
as they provide relatively less expensive therapies with higher levels of efficacy. For
example, medically assisted treatment (MAT) with methadone and buprenorphine have
proven to effectively reduce opioid addiction (Meinhoffer & Witman, 2018). These
services are also more likely to be covered by private insurance. The ACA requires
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health insurance plans to cover substance use disorders services as one of the ten
essential health benefits. Therefore, preventive and rehabilitation services must be
offered at parity with other essential benefits (Mclellan & Woodworth, 2014). Another
possible explanation for the reduction in opioid use and abuse attributed to the coverage
expansion is that the general health of young adults may have improved as a result of
entering coordinated care.
My findings are in line with previous studies showing that dependent coverage
provision reduced the share of uninsured young adults and changed the settings in
which individuals with substance disorders received attention, by increasing treatment
utilization in outpatient settings (Meinhoffer & Witman, 2018; Saloner et al., 2018).
These results overall reflect the importance of assessing the possible externalities caused
by a large expansion in health insurance.
The results in this study imply that the expansion of private coverage, which did
not directly target opioid abuse, could have plausibly contributed to curbing the opioid
epidemic instead of enhancing it.
9 Conclusion
The United States is currently experiencing an unprecedented drug crisis. Opioid pain
relievers, which have a legitimate medical function have been the main driver of the
epidemic. This paper evaluates the extent to which expansion in medical access to
prescriptions for opioid pain relievers to a population that is at higher risk of misuse
and abuse contributed to the problem. Using data from the 2008-2014 waves of the
NSDUH and a non-linear difference-in-difference design, I analyze the impacts of the
Affordable Care Act’s dependent coverage provision on opioid use disorders. My find-
ings shed light on the important role that health insurance plays in the rehabilitation
of individuals with substance use disorders and suggest that increased access to pre-
venting and rehabilitation services in more appropriate settings have the potential of
curbing the opioid epidemic.
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Table 1: Treatments vs Control Demographics
(1) (2) (3) (4)
Control Treated Control Treated
2008-2010 2008-2010 2008-2014 2008-2014
Female 0.536 0.533 0.537 0.534
Male 0.464 0.467 0.463 0.466
Hispanic 0.198 0.177 0.190 0.177
Black 0.119 0.127 0.121 0.133
White 0.584 0.602 0.586 0.593
Other Race 0.099 0.094 0.103 0.097
Married 0.406 0.217 0.394 0.204
Less Than HS 0.154 0.145 0.141 0.130
High School 0.279 0.292 0.267 0.295
Some College 0.264 0.306 0.277 0.312
College 0.303 0.258 0.316 0.263
Less Than $20,000 0.212 0.297 0.210 0.305
$20,000-$49,000 0.409 0.395 0.405 0.391
$50,000-$74,000 0.192 0.148 0.188 0.142
$75,000 or more 0.188 0.160 0.198 0.163
Observations 8205 27163 19849 61612
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Table 2: Insurance Status - Descriptive Statistics
(1) (2) (3) (4)
Control Treated Control Treated
2008-2010 2008-2010 2008-2014 2008-2014
Any Insurance 0.730 0.697 0.735 0.731
Private Insurance 0.561 0.513 0.552 0.536
Medicaid 0.135 0.139 0.147 0.147
No Insurance 0.270 0.303 0.265 0.269
Observations 8169 27020 19743 61177
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Table 3: Opioid Pain Relievers Use Disorders - Descriptive Statistics
(1) (2) (3) (4)
Control Treated Control Treated
2008-2010 2008-2010 2008-2014 2008-2014
Misuse Past Year 0.083 0.107 0.079 0.096
Misuse Past Month 0.032 0.045 0.032 0.039
Abuse/Dependence 0.013 0.018 0.014 0.018
Abuse 0.002 0.004 0.002 0.003
Observations 8199 27124 19827 61531
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Table 4: Treatment Settings for Substance Use Disorders - Descriptive Statistics
(1) (2) (3) (4)
Control Treated Control Treated
2008-2010 2008-2010 2008-2014 2008-2014
Emergency Room 0.049 0.058 0.075 0.069
Inpatient Treatment 0.181 0.199 0.241 0.226
Outpatient Treatment 0.490 0.398 0.495 0.439
Treatment For Opioids 0.255 0.247 0.320 0.304
Observations 204 788 493 1669
Inpatient setting is defined as treatment received overnight at a hospital or a
residential rehabilitation facility.
Outpatient setting is defined as treatment received at a rehabilitation facility,
and [private doctor’s office.
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DD 0.064∗∗∗ 0.067∗∗∗ -0.064∗∗∗
(0.006) (0.006) (0.006)
Female 0.095∗∗∗ -0.031∗∗∗ -0.095∗∗∗
(0.004) (0.004) (0.004)
Black -0.087∗∗∗ -0.241∗∗∗ 0.087∗∗∗
(0.008) (0.006) (0.008)
Hispanic -0.193∗∗∗ -0.269∗∗∗ 0.193∗∗∗
(0.004) (0.004) (0.004)
Metropolitan Area 0.047∗∗∗ 0.105∗∗∗ -0.047∗∗∗
(0.004) (0.004) (0.004)
Observations 81066 81187 81066
Standard errors in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
Table 5 shows the marginal effects on insurance status.
Regressions include age and year fixed effects.









































































































































































































































































































































































































































































































Table 7: Effect of the Young Adult Provision on Treatment Settings For Substance use
Disorders
(1) (2) (3) (4)
Emergency Inpatient Outpatient Opioid
Room Treatment Treatment Treatment
DD -0.007 -0.041 0.074∗∗ 0.009
(0.008) (0.026) (0.032) (0.037)
Female 0.012∗∗∗ 0.008 0.082∗∗∗ 0.086∗∗∗
(0.004) (0.018) (0.017) (0.017)
Black -0.021∗∗ -0.050∗ -0.131∗∗∗ -0.296∗∗∗
(0.009) (0.028) (0.029) (0.042)
Hispanic -0.004 -0.052 -0.110∗∗∗ -0.189∗∗∗
(0.005) (0.033) (0.038) (0.028)
Metropolitan Area 0.014∗∗∗ 0.051∗∗ -0.007 0.002
(0.005) (0.026) (0.026) (0.021)
Observations 6208 2169 2169 2162
Standard errors in parentheses
∗ p < 0.10, ∗∗ p < 0.05, ∗∗∗ p < 0.01
Table 7 shows the marginal effects on location settings for treatment.
Regressions include age and year fixed effects. Standard errors are
clustered by age and year.
Inpatient setting is defined as treatment received overnight at a hospital
or a residential rehabilitation facility.
Outpatient setting is defined as treatment received at a rehabilitation
facility, mental health care center or a private doctor’s office
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